Product Catalogue

Search medicines to find what you're looking for.

Print

Feel free to print the current page view

Filters

Alphabet

Toggle

Product TA

Toggle

Showing 20 of 243 results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

A Pharmacokinetic and Safety study comparing Fluticasone Propionate and Albuterol Sulfate to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

respiratory-icon.png
Prescription:
NCT06290102
View product The primary objectives of this study are to determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 in participants with asthma, to compare the PK profiles of Fp for different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI), and to compare the PK profiles of ABS between the 2 different strengths of TEV-56248.

A Study to Assess New Formulations of TEV-56286

brain-icon.png
Prescription:
NCT06911567
View product The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

brain-icon.png
Prescription:
NCT00349193
View product Please refer to ClinicalTrials.gov for a description of the trial

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/​Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

respiratory-icon.png
Prescription:
NCT06052267
View product The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). The secondary objectives are: To evaluate the efficacy of Fp/ABS low dose compared to ABS and the effect on systemic corticosteroid (SCS) exposure. To evaluate the safety and tolerability of Fp/ABS.The duration for each participant will be a minimum of 28 weeks including 2 weeks of screening, 2-4 weeks of run-in period and a double blind treatment period of minimum 24 weeks, however due to the event-driven nature of this study, the duration may range up to approximately 42 months depending on the timing when the participant was enrolled to the study, and when the study reaches its completion criteria.

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

inflammation-icon.png
Prescription:
NCT06807463
View product Primary objectives: The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. Secondary objective:A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.The expected trial duration per participant is approximately 86 weeks.

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (TOPAS-MSA)

brain-icon.png
Prescription:
NCT06568237
View product Primary objectives: The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). Secondary objectives: A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.

A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

allergy-icon.png
Prescription:
NCT06625177
View product The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.

Absolute Bioavailability of Reslizumab in Healthy Subjects

disease-icon.png
Prescription:
NCT01990443
View product Please refer to ClinicalTrials.gov for a description of the trial

Adenovirus Vaccine Pregnancy Registry

inflammation-icon.png
Prescription:
NCT01584037
View product Please refer to ClinicalTrials.gov for a description of the trial

Albuterol HFA MDI in Pediatric Participants With Asthma

respiratory-icon.png
Prescription:
NCT00577655
View product Please refer to ClinicalTrials.gov for a description of the trial

An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients

respiratory-icon.png
Prescription:
NCT02315144
View product Please refer to ClinicalTrials.gov for a description of the trial

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

headache-icon.png
Prescription:
NCT03308968
View product Please refer to ClinicalTrials.gov for a description of the trial

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

brain-icon.png
Prescription:
NCT07197866
View product The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks

Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication

psychiatry-icon.png
Prescription:
NCT02184767
View product Please refer to ClinicalTrials.gov for a description of the trial

Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older

allergy-icon.png
Prescription:
NCT00854360
View product Please refer to ClinicalTrials.gov for a description of the trial

Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo

brain-icon.png
Prescription:
NCT01067521
View product Please refer to ClinicalTrials.gov for a description of the trial

Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency

muscle-icon.png
Prescription:
NCT00455260
View product Please refer to ClinicalTrials.gov for a description of the trial

Assessment of LBR-101 In Chronic Migraine

headache-icon.png
Prescription:
NCT02021773
View product Please refer to ClinicalTrials.gov for a description of the trial

Azilect + Antidepressant Chart Review

psychiatry-icon.png
Prescription:
NCT00955604
View product Please refer to ClinicalTrials.gov for a description of the trial

Azilect® In Wearing-Off

brain-icon.png
Prescription:
NCT02384512
View product Please refer to ClinicalTrials.gov for a description of the trial